Helix BioPharma (TSE:HBP)
TSX:HBP
Want to see TSE:HBP full AI Analyst Report?
HBP Stock Chart & Stats
C$2.40
-C$0.03(-3.23%)
At close: 4:00 PM EST
C$2.40
-C$0.03(-3.23%)
Day’s Range― - ―
52-Week RangeC$0.84 - C$5.40
Previous CloseN/A
Volume518.00
Average Volume (3M)13.00K
Market Cap
C$124.50M
Enterprise ValueC$124.82M
Total Cash (Recent Filing)C$31.00K
Total Debt (Recent Filing)C$359.00K
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Equity CushionVery low debt (TTM debt-to-equity ~0.02) and a positive equity base (~$15.4M) materially reduce near-term refinancing and default risk. This balance sheet positioning gives management flexibility to fund clinical programs, makes milestone financing easier, and lowers interest burden over the coming months.
Focused R&D PortfolioA concentrated strategy around R&D and management of preclinical/clinical oncology assets reduces operational complexity and preserves capital compared with running commercial operations. This model supports value creation through clinical milestones, partnerships, or licensing deals that are durable over a multi-month horizon.
Improving Loss TrendReported losses have narrowed versus prior years (improvements versus 2024 and 2021), indicating management has been trimming costs or improving operational efficiency. If sustained, lower cash burn extends the runway, reduces near-term financing urgency, and increases the probability of reaching clinical inflection points without immediate dilutive raises.
Bears Say
No Revenue & Ongoing LossesThe company remains pre-revenue with a TTM net loss of about $4.2M, meaning long-term viability depends on successful development or external deals. Without a commercial revenue base, sustainable profitability is uncertain and the business is structurally dependent on milestone outcomes and external financing.
Consistent Negative Cash FlowOperating and free cash flow are persistently negative (TTM free cash flow ~ -$3.7M), creating ongoing structural funding needs. This chronic cash burn forces reliance on equity or partner financing, increasing dilution risk and potentially constraining program timelines if capital access tightens.
Historical Balance Sheet VolatilityPast periods of negative equity and balance sheet volatility (2021–2024) reflect recurring capital stress and prior dilution events. This history can impair investor and partner confidence, elevate financing costs, and make the firm more vulnerable to adverse trial outcomes or cost increases over the medium term.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.84 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$124.50M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Jun 17, 2026 which is in 27 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Mar 16, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.793%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---